The global nuclear medicine market size accounted for USD 11.85 billion in 2024, grew to USD 13.21 billion in 2025 and is predicted to surpass around USD 35.04 billion by 2034, representing a healthy CAGR of 11.45% between 2025 and 2034. The North America nuclear medicine market size is calculated at USD 5.69 billion in 2024 and is expected to grow at a fastest CAGR of 11.56% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Nuclear Medicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Nuclear Medicine Market, by Product, 2025-2034
8.1.1 Diagnostic Products
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Therapeutic Products
8.1.2.1. Market Revenue and Forecast (2022-2034)
9.1. Nuclear Medicine Market, by Application, 2025-2034
9.1.1. Cardiology
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Neurology
9.1.2.1. Market Revenue and Forecast (2022-2034)
9.1.3. Oncology
9.1.3.1. Market Revenue and Forecast (2022-2034)
9.1.4. Thyroid
9.1.4.1. Market Revenue and Forecast (2022-2034)
9.1.5. Lymphoma
9.1.5.1. Market Revenue and Forecast (2022-2034)
9.1.6. Bone Metastasis
9.1.6.1. Market Revenue and Forecast (2022-2034)
9.1.7. Endocrine Tumor
9.1.7.1. Market Revenue and Forecast (2022-2034)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2022-2034)
10.1. Nuclear Medicine Market, by End-user, 2025-2034
10.1.1. Endocrine Tumor
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Endocrine Tumor
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2022-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2022-2034)
11.1.2. Market Revenue and Forecast, by Application (2022-2034)
11.1.3. Market Revenue and Forecast, by End-user (2022-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2022-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2022-2034)
11.1.4.3. Market Revenue and Forecast, by End-user (2022-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2022-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2022-2034)
11.1.5.3. Market Revenue and Forecast, by End-user (2022-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2022-2034)
11.2.2. Market Revenue and Forecast, by Application (2022-2034)
11.2.3. Market Revenue and Forecast, by End-user (2022-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2022-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2022-2034)
11.2.4.3. Market Revenue and Forecast, by End-user (2022-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2022-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2022-2034)
11.2.5.3. Market Revenue and Forecast, by End-user (2022-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2022-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2022-2034)
11.2.6.3. Market Revenue and Forecast, by End-user (2022-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2022-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2022-2034)
11.2.7.3. Market Revenue and Forecast, by End-user (2022-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2022-2034)
11.3.2. Market Revenue and Forecast, by Application (2022-2034)
11.3.3. Market Revenue and Forecast, by End-user (2022-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2022-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2022-2034)
11.3.4.3. Market Revenue and Forecast, by End-user (2022-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2022-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2022-2034)
11.3.5.3. Market Revenue and Forecast, by End-user (2022-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2022-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2022-2034)
11.3.6.3. Market Revenue and Forecast, by End-user (2022-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2022-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2022-2034)
11.3.7.3. Market Revenue and Forecast, by End-user (2022-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2022-2034)
11.4.2. Market Revenue and Forecast, by Application (2022-2034)
11.4.3. Market Revenue and Forecast, by End-user (2022-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2022-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2022-2034)
11.4.4.3. Market Revenue and Forecast, by End-user (2022-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2022-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2022-2034)
11.4.5.3. Market Revenue and Forecast, by End-user (2022-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2022-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2022-2034)
11.4.6.3. Market Revenue and Forecast, by End-user (2022-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2022-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2022-2034)
11.4.7.3. Market Revenue and Forecast, by End-user (2022-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2022-2034)
11.5.2. Market Revenue and Forecast, by Application (2022-2034)
11.5.3. Market Revenue and Forecast, by End-user (2022-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2022-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2022-2034)
11.5.4.3. Market Revenue and Forecast, by End-user (2022-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2022-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2022-2034)
11.5.5.3. Market Revenue and Forecast, by End-user (2022-2034)
12.1. GE Healthcare
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Nordion (Canada), Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bracco Imaging S.P.A
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Jubilant Life Sciences Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. NTP Radioisotopes SOC Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. The Australian Nuclear Science and Technology Organization
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. The institute for radioelements (IRE)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Eczacıbaşı-Monrol
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eckert & Ziegler
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Lantheus Medical Imaging, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample